Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
Last trade$1.56
Day change-$0.04 (-2.50%)
Day range$1.45 – $1.67
Volume1,421,560
Market cap$107M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for ADAG.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for ADAG.
Recent news
Company coverage with links to the original publishers.
Adagene Inc. and City of Hope announced the launch of a Phase 1 clinical trial to evaluate a combination therapy of ivonescimab and muzastotug (ADG126) for patients with advanced microsatellite stable colorectal cancer. The trial will enroll up to 36 patients and aims to determine optimal dosing before potentially combining the immunotherapy with chemotherapy drugs 5-FU and irinotecan. The study is investigator-initiated and designed to accelerate treatment options for patients whose disease has resisted standard treatments.
Adagene Inc. (Nasdaq: ADAG), a clinical-stage biotechnology company, announced that senior management will participate in a fireside chat and one-on-one meetings at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference on November 9-11, 2026 in Boston. The company is advancing its lead clinical program muzastotug (ADG126), a masked anti-CTLA-4 SAFEbody currently in Phase 1b/2 and Phase 2 studies for microsatellite stable metastatic colorectal cancer in combination with anti-PD-1 therapy.
Adagene reported 29% overall response rate for muzastotug (ADG126) in MSS colorectal cancer patients at the 20 mg/kg dose, with median overall survival of 19.4 months at 10 mg/kg dose. The company demonstrated improved tolerability with 4% discontinuation rate and no Grade 4-5 adverse events across 67 patients. With $74.5 million in cash as of December 31, 2025, Adagene expects runway into early 2028 and plans to initiate a registration trial once optimal dose is established.
Adagene has signed a licensing agreement with Third Arc Bio to utilize its SAFEbody technology platform for developing two masked CD3 T cell engagers targeting unique tumor-associated antigens. The deal includes an upfront payment of $5 million and potential milestone payments up to $840 million.
Adagene initiated a Phase 2 clinical trial for muzastotug (ADG126) in combination with KEYTRUDA for microsatellite stable colorectal cancer, randomizing patients to 10 or 20 mg/kg doses with anticipated trial completion in early 2027.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.